Boehringer May Sell U.S. Generics Unit

Jan 15, 2015

Bloomberg

According to Bloomberg sources, Boehringer Ingelheim is considering the sale of its U.S. Roxane Labs business, valued at as much as $2.4 billion.

Sources say the German drugmaker is working with Morgan Stanley on the possible sale of Ohio-based Roxane Labs, which is Boehringer's generic pharmaceutical business.

A Boehringer spokewoman would only confirm that the company is "exploring strategic options" when contacted by Bloomberg.

Read the Bloomberg release

 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments